HealthInvest Partners AB Takes $2.24 Million Position in DexCom, Inc. (NASDAQ:DXCM)

HealthInvest Partners AB purchased a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 18,057 shares of the medical device company's stock, valued at approximately $2,241,000. DexCom comprises 1.8% of HealthInvest Partners AB's portfolio, making the stock its 21st biggest position.

Several other large investors also recently bought and sold shares of DXCM. KB Financial Partners LLC purchased a new stake in DexCom in the 1st quarter valued at about $72,000. Bartlett & CO. Wealth Management LLC purchased a new position in DexCom during the 4th quarter valued at about $27,000. Valley National Advisers Inc. grew its position in DexCom by 73.0% in the 4th quarter. Valley National Advisers Inc. now owns 244 shares of the medical device company's stock valued at $30,000 after acquiring an additional 103 shares in the last quarter. MV Capital Management Inc. increased its stake in DexCom by 99.3% during the 4th quarter. MV Capital Management Inc. now owns 277 shares of the medical device company's stock worth $34,000 after buying an additional 138 shares during the period. Finally, Harbour Investments Inc. lifted its holdings in DexCom by 55.6% during the 3rd quarter. Harbour Investments Inc. now owns 336 shares of the medical device company's stock worth $31,000 after buying an additional 120 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company's stock.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 49,633 shares of the business's stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the sale, the chief executive officer now owns 283,893 shares of the company's stock, valued at $39,262,401.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, EVP Michael Jon Brown sold 2,624 shares of the business's stock in a transaction dated Thursday, March 28th. The shares were sold at an average price of $140.04, for a total value of $367,464.96. Following the sale, the executive vice president now directly owns 68,682 shares in the company, valued at approximately $9,618,227.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Kevin R. Sayer sold 49,633 shares of DexCom stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $138.30, for a total transaction of $6,864,243.90. Following the transaction, the chief executive officer now owns 283,893 shares of the company's stock, valued at approximately $39,262,401.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 187,385 shares of company stock valued at $25,256,617. 0.41% of the stock is owned by company insiders.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded up $1.96 during midday trading on Tuesday, hitting $136.52. The stock had a trading volume of 3,036,341 shares, compared to its average volume of 2,992,702. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The company has a current ratio of 2.84, a quick ratio of 2.48 and a debt-to-equity ratio of 1.18. The stock has a 50 day moving average price of $128.82 and a two-hundred day moving average price of $115.85. The company has a market capitalization of $52.63 billion, a PE ratio of 104.63, a P/E/G ratio of 2.34 and a beta of 1.20.

DexCom (NASDAQ:DXCM - Get Free Report) last released its earnings results on Thursday, February 8th. The medical device company reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.43 by $0.07. DexCom had a return on equity of 28.31% and a net margin of 14.95%. The company had revenue of $1.03 billion for the quarter, compared to analysts' expectations of $1.02 billion. During the same quarter in the previous year, the firm posted $0.34 EPS. The firm's quarterly revenue was up 26.9% on a year-over-year basis. As a group, equities analysts predict that DexCom, Inc. will post 1.76 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on DXCM. Raymond James increased their price objective on DexCom from $147.00 to $151.00 and gave the company a "strong-buy" rating in a research note on Tuesday, January 23rd. StockNews.com upgraded shares of DexCom from a "hold" rating to a "buy" rating in a research note on Wednesday, April 3rd. Royal Bank of Canada began coverage on shares of DexCom in a research report on Tuesday, March 12th. They set an "outperform" rating and a $165.00 price objective for the company. UBS Group raised their price target on DexCom from $153.00 to $163.00 and gave the company a "buy" rating in a research note on Wednesday, April 10th. Finally, Citigroup raised their target price on DexCom from $148.00 to $161.00 and gave the stock a "buy" rating in a research report on Wednesday, April 3rd. Two research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $141.40.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.